一分钟看懂
这是一项关于肾细胞癌的I 期 / II 期研究，登记的药物或干预包括Belzutifan；Zanzalintinib，当前状态为招募中。登记地点显示中国San Francisco、Mineola、New York、Durham等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Belzutifan；Zanzalintinib · I 期 / II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- UCSF Medical Center at Mission Bay ( Site 5008) · San Francisco
- Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 5026) · Mineola
- Laura and Isaac Perlmutter Cancer Center ( Site 5016) · New York
- Memorial Sloan Kettering Cancer Center ( Site 5002) · New York
- Duke Cancer Institute ( Site 5015) · Durham
- UPMC Cancer Center/Hillman Cancer Center ( Site 5017) · Pittsburgh
- Vanderbilt University Medical Center ( Site 5004) · Nashville
- Centro de Estudios Clínicos SAGA ( Site 6110) · Santiago
- Bradfordhill ( Site 6101) · Santiago
- C.H.U. de Strasbourg Hopital de Hautepierre ( Site 5203) · Strasbourg
- Institut Claudius Regaud ( Site 5200) · Toulouse
- Centre Eugene Marquis ( Site 5205) · Rennes
- Institut De Cancerologie De Lorraine ( Site 5204) · Vandœuvre-lès-Nancy
- Gustave Roussy ( Site 5202) · Villejuif
- Rambam Health Care Campus ( Site 5500) · Haifa
- Rabin Medical Center ( Site 5502) · Petah Tikva
- Sheba Medical Center ( Site 5501) · Ramat Gan
- Sourasky Medical Center ( Site 5503) · Tel Aviv
- Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 6201) · Bydgoszcz
- Narodowy Instytut Onkologii im. Marii Skłodowskiej Curie ( Site 6203) · Warsaw
- Uniwersyteckie Centrum Kliniczne ( Site 6202) · Gdansk
- Severance Hospital ( Site 5802) · Seoul
- Asan Medical Center ( Site 5800) · Seoul
- Samsung Medical Center ( Site 5801) · Seoul
- HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON ( Site 5302) · Madrid
- Hospital Universitario Ramon y Cajal ( Site 5301) · Madrid
- Hospital Universitari Vall d'Hebron ( Site 5300) · Barcelona
- Western General Hospital ( Site 5402) · Edinburgh
- The Beatson West of Scotland Cancer Centre ( Site 5405) · Glasgow
- St Bartholomew's Hospital ( Site 5401) · London
公开的入选条件
- The main inclusion criteria include but are not limited to the following:
- * Has a histologically confirmed diagnosis of unresectable locally advanced/metastatic renal cell carcinoma (RCC) with clear cell component
- * Has received no other prior systemic therapy for treatment of advanced/metastatic clear cell renal cell carcinoma (ccRCC) except for adjuvant programmed cell death ligand 1 (PD-(L)1) therapy
- * Has disease recurrence during adjuvant anti- PD-(L)1 therapy or ≤24 months following the last dose of adjuvant anti-PD-(L)1 therapy
- * Is able to swallow oral medication
- * Submits an archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated
- * Participants receiving bone resorptive therapy (must have therapy initiated at least 2 weeks before allocation/randomization)
- * Has adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP ≤140/90 mm Hg with no change in antihypertensive medications within 1 week before allocation/randomization
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07049926；登记信息更新于 2026-09-17。